Press Resease

Soft Tissue Allografts Market - By Type (Collagen Allograft, Meniscus Allograft, Dental Allograft, Cartilage, Tendon Allograft, and Amniotic Allograft), By Application (Wound Care, Dentistry, Orthopedic, and Others), By End-User (Dental Clinics, Orthopedic Clinics, Ambulatory Surgical Centers, Hospitals, and Aesthetic Clinics), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

Published Date: 25-Sep-2020 Category: Medical Device Report Format : PDF Pages: 110 Report Code: ZMR-2766 Status : Published

Global Soft Tissue Allografts market, which accrued revenue worth 3.61 (USD Billion) in 2019, is slated to register a CAGR of nearly 6.4% over 2020-2026.

Description

The global Soft Tissue Allografts market, which accrued revenue worth 3.61 (USD Billion) in 2019, is slated to register a CAGR of nearly 6.4% over 2020-2026. The report offers valuation and analysis of Soft Tissue Allografts market on a global as well as regional level. The study offers a comprehensive assessment of the industry competition, limitations, sales estimates, avenues, current & emerging trends, and industry-validated market data. The report offers historical data from 2016 to 2019 along with a forecast from 2020 to 2026 based on value (USD Billion).

Introduction

Soft tissue allografts are the key substitute tissue for reconstructing of deficient ligaments, osteochondral defects, and torn menisci at the time of surgery of knees. Furthermore, massive demand for allografts for the purpose of soft tissue reconstruction is due to need for stable knee helping in offering protection against more damage to ligaments & restoring of knee functions. Additionally, allografts provide myriad benefits as compared to autografts in musculoskeletal reconstructions like anterior cruciate ligament reconstruction.   

Furthermore, soft tissue allografts provide better graft availability and reduction in the rate of morbidity in Orthopaedic reconstructive methods. Apparently, these Application  have proved to be valuable modes of treatment for patients having many kinds of injuries. For instance, these Application  are useful for athletes suffering from muscular-skeletal sports injuries and patients inflicted with severe burn injuries. The product has also found application in healthcare sector where patient need solid organ transplantation.   

Market Growth Dynamics

Escalating demand for soft tissue allografts in various sports events is anticipated to make lucrative contributions towards the overall market size in the coming years.  Apart from this, humungous use of the product in orthopedic surgeries as well as oral implants will catalyze the expansion of the soft tissue allografts industry over the years ahead. In addition to this, surge in the aging population prone to knee or ligament disorders and osteoarthritis will define the product requirement, thereby translating into protuberant growth for soft tissue allograft market.

Apparently, constant focus of the industry players on developing user-friendly products with additional features at reasonable costs and successful implementation of various positioning strategies will engineer the market progression in the years ahead. With rise in the road collisions and injuries during sports activities, the soft tissue allografts industry is anticipated to gain traction over the years to come.

North America To Be A Key Proponent Of Market Growth Over 2020-2026

The region is projected to play a leading role in influencing the market growth in the year ahead. Its contributions to the overall market earnings can be attributed to humungous presence of key product manufacturers and rapid acceptance of new technologies in the healthcare & medical sectors. Additionally, increase in the cases of diabetics with foot ulcers and inflation in the rate of surgeries on anterior cruciate ligament in countries like the U.S. and Canada will promulgate the growth of the industry in the sub-continent over the forthcoming years.

Key participants influencing the market expansion are Globus Medical, Inc.; B. Braun Melsungen AG; Alliqua BioMedical, Inc.; Zimmer Biomet; Straumann Holding AG; AlloSource; Integra LifeSciences Corporation; MiMedix Group; AlonSource Group; Lattice Biologics Ltd.; CONMED Corporation; RTI Surgical, Inc.; Organogenesis, Inc.; Osiris Therapeutics; C. R. Bard, Inc. (Davol, Inc.); Xtant Medical; and Arthrex.

The global soft tissue allografts market is segmented as follows:

By type:

  • Cartilage
  • Dental Allograft
  • Meniscus Allograft
  • Collagen Allograft
  • Amniotic Allograft
  • Tendon Allograft

By application:

  • Orthopedic
  • Dentistry
  • Wound Care
  • Others

By end-user:

  • Dental Clinics
  • Orthopedic Clinics
  • Ambulatory Surgical Centers
  • Hospitals
  • Aesthetic Clinics

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Soft Tissue Allograft Market , 2016–2026 (USD Billion)
    • 2.2. Soft Tissue Allograft Market : Snapshot
  • Chapter 3. Global Soft Tissue Allograft Market – Industry Analysis
    • 3.1. Soft Tissue Allograft Market : Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Surge in the aging population prone to knee or ligament disorders and osteoarthritis will define the product requirement, thereby translating into protuberant growth for soft tissue allograft market.
      • 3.2.2. With rise in the road cullisions and injuries during sports activities, the soft tissue allografts industry is anticipated to gain traction over the years to come.
    • 3.3. Porter’s Five Forces Analysis
    • 3.4. Market Attractiveness Analysis
      • 3.4.1. Market attractiveness analysis By Type
      • 3.4.2. Market attractiveness analysis By Application
      • 3.4.3. Market attractiveness analysis By End-User
  • Chapter 4. Global Soft Tissue Allograft Market – Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Soft Tissue Allograft Market : company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Product launches
      • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Soft Tissue Allograft Market – Type Analysis
    • 5.1. Global Soft Tissue Allograft Market overview: By Type
      • 5.1.1. Global Soft Tissue Allograft Market share, By Type , 2019 and 2026
    • 5.2. Cullagen Allograft
      • 5.2.1. Global Soft Tissue Allograft Market By Cullagen Allograft, 2016–2026 (USD Billion)
    • 5.3. Meniscus Allograft
      • 5.3.1. Global Soft Tissue Allograft Market By Meniscus Allograft, 2016–2026 (USD Billion)
    • 5.4. Dental Allograft
      • 5.4.1. Global Soft Tissue Allograft Market By Dental Allograft, 2016–2026 (USD Billion)
    • 5.5. Cartilage
      • 5.5.1. Global Soft Tissue Allograft Market By Cartilage, 2016–2026 (USD Billion)
    • 5.6. Tendon Allograft
      • 5.6.1. Global Soft Tissue Allograft Market By Tendon Allograft, 2016–2026 (USD Billion)
    • 5.7. Amniotic Allograft
      • 5.7.1. Global Soft Tissue Allograft Market By Amniotic Allograft, 2016–2026 (USD Billion)
  • Chapter 6. Global Soft Tissue Allograft Market – Application Analysis
    • 6.1. Global Soft Tissue Allograft Market overview: By Application
      • 6.1.1. Global Soft Tissue Allograft Market share, By Application , 2019 and 2026
    • 6.2. Wound Care
      • 6.2.1. Global Soft Tissue Allograft Market By Wound Care , 2016–2026 (USD Billion)
    • 6.3. Dentistry
      • 6.3.1. Global Soft Tissue Allograft Market By Dentistry, 2016–2026 (USD Billion)
    • 6.4. Orthopedic
      • 6.4.1. Global Soft Tissue Allograft Market By Orthopedic, 2016–2026 (USD Billion)
    • 6.5. Others
      • 6.5.1. Global Soft Tissue Allograft Market By Others, 2016–2026 (USD Billion)
  • Chapter 7. Global Soft Tissue Allograft Market – End-User Analysis
    • 7.1. Global Soft Tissue Allograft Market overview: By End-User
      • 7.1.1. Global Soft Tissue Allograft Market share, By End-User , 2019 and 2026
    • 7.2. Dental Clinics
      • 7.2.1. Global Soft Tissue Allograft Market By Dental Clinics, 2016–2026 (USD Billion)
    • 7.3. Orthopedic Clinics
      • 7.3.1. Global Soft Tissue Allograft Market By Orthopedic Clinics, 2016–2026 (USD Billion)
    • 7.4. Ambulatory Surgical Centers
      • 7.4.1. Global Soft Tissue Allograft Market By Ambulatory Surgical Centers, 2016–2026 (USD Billion)
    • 7.5. Aesthetic Clinics
    • 7.6. Global Soft Tissue Allograft Market By Aesthetic Clinics, 2016–2026 (USD Billion)
    • 7.7. Hospitals
      • 7.7.1. Global Soft Tissue Allograft Market By Hospitals, 2016–2026 (USD Billion)
  • Chapter 8. Company Profiles
    • 8.1. C. R. Bard, Inc.
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Product Portfolio
      • 8.1.4. Business Strategy
      • 8.1.5. Recent Developments
    • 8.2. Alliqua BioMedical, Inc.
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Product Portfolio
      • 8.2.4. Business Strategy
      • 8.2.5. Recent Developments
    • 8.3. Zimmer Biomet
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Product Portfolio
      • 8.3.4. Business Strategy
      • 8.3.5. Recent Developments
    • 8.4. Lattice Biulogics Ltd.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Product Portfolio
      • 8.4.4. Business Strategy
      • 8.4.5. Recent Developments
    • 8.5. MiMedix Group
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Product Portfolio
      • 8.5.4. Business Strategy
      • 8.5.5. Recent Development
    • 8.6. AlonSource Group
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Product Portfolio
      • 8.6.4. Business Strategy
      • 8.6.5. Recent Development
    • 8.7. CONMED Corporation
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Product Portfolio
      • 8.7.4. Business Strategy
      • 8.7.5. Recent Development
    • 8.8. AlloSource
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Product Portfolio
      • 8.8.4. Business Strategy
      • 8.8.5. Recent Development
    • 8.9. RTI Surgical, Inc.
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Product Portfolio
      • 8.9.4. Business Strategy
      • 8.9.5. Recent Development
    • 8.10. Organogenesis, Inc.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Product Portfolio
      • 8.10.4. Business Strategy
      • 8.10.5. Recent Development
    • 8.11. Integra LifeSciences Corporation
      • 8.11.1. Overview
      • 8.11.2. Financials
      • 8.11.3. Product Portfolio
      • 8.11.4. Business Strategy
      • 8.11.5. Recent Development
    • 8.12. Osiris Therapeutics
      • 8.12.1. Overview
      • 8.12.2. Financials
      • 8.12.3. Product Portfolio
      • 8.12.4. Business Strategy
      • 8.12.5. Recent Development
    • 8.13. Straumann Hulding AG
      • 8.13.1. Overview
      • 8.13.2. Financials
      • 8.13.3. Product Portfolio
      • 8.13.4. Business Strategy
      • 8.13.5. Recent Development
    • 8.14. Globus Medical, Inc.
      • 8.14.1. Overview
      • 8.14.2. Financials
      • 8.14.3. Product Portfolio
      • 8.14.4. Business Strategy
      • 8.14.5. Recent Development
    • 8.15. Xtant Medical
      • 8.15.1. Overview
      • 8.15.2. Financials
      • 8.15.3. Product Portfolio
      • 8.15.4. Business Strategy
      • 8.15.5. Recent Development
    • 8.16. B. Braun Melsungen AG
      • 8.16.1. Overview
      • 8.16.2. Financials
      • 8.16.3. Product Portfolio
      • 8.16.4. Business Strategy
      • 8.16.5. Recent Development
    • 8.17. Arthrex
      • 8.17.1. Overview
      • 8.17.2. Financials
      • 8.17.3. Product Portfolio
      • 8.17.4. Business Strategy
      • 8.17.5. Recent Development

Methodology


Frequently Asked Questions

Escalating demand for soft tissue allografts in various sports events is anticipated to make lucrative contributions towards the overall market size in the coming years.  Apart from this, humungous use of the product in orthopedic surgeries as well as oral implants will catalyze the expansion of the soft tissue allografts industry over the years ahead. Apparently, constant focus of the industry players on developing user-friendly products with additional features at reasonable costs and successful implementation of various positioning strategies will engineer the market progression in the years ahead.

According to Zion Market Research report, The global Soft Tissue Allograft Market, which accrued revenue worth 3.61 (USD Billion) in 2019, is slated to register a CAGR of nearly 6.4% over 2020-2026.

North America is likely to make noteworthy contributions towards overall market revenue. The growth of the industry in the sub-continent over the estimated timespan is its contributions to the overall market earnings can be attributed to humungous presence of key product manufacturers and rapid acceptance of new technologies in the healthcare & medical sectors. Additionally, increase in the cases of diabetics with foot ulcers and inflation in the rate of surgeries on anterior cruciate ligament in countries like the U.S. and Canada will promulgate the growth of the industry in the sub-continent over the forthcoming years.

The key players profiled in the report include Globus Medical, Inc.; B. Braun Melsungen AG; Alliqua BioMedical, Inc.; Zimmer Biomet; Straumann Holding AG; AlloSource; Integra LifeSciences Corporation; MiMedix Group; AlonSource Group; Lattice Biologics Ltd.; CONMED Corporation; RTI Surgical, Inc.; Organogenesis, Inc.; Osiris Therapeutics; C. R. Bard, Inc. (Davol, Inc.); Xtant Medical; and Arthrex. With new players entering the market, the market is likely to be highly competitive and hence the existing players are focusing on product innovations keeping the cost of product reasonable with a view to acquire desired profits.

Office Address

Corporate Office
Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office
3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #
US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com